ASRT · Assertio Holdings, Inc.
$23.50
+0.00 (+0.00%)
At close · Jun 29
Market Cap
$151.86M
Shares
6.46M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$118.71M
-5%
FY2025
Net Income
-$30.38M
-40.7%
FY2025
Gross Margin
85.74%
+4.4pp
FY2021
Operating Margin
-18.14%
+1.4pp
FY2025
Diluted EPS
-$4.74
-39.4%
FY2025
Operating Cash Flow
-$28.18M
-206.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $102.16M | $118.71M | $124.96M | $152.07M | $156.23M | $111.01M | $106.28M | $229.5M | |
| — | — | — | — | — | $15.83M | $19.87M | $9.51M | |
| — | — | — | — | — | $95.18M | $86.4M | $220M | |
| — | — | — | — | — | 85.74% | 81.3% | 95.86% | |
| $1.71M | $1.69M | $3.82M | $2.84M | $0 | $0 | $4.21M | $10.11M | |
| $66.46M | $69M | $75.05M | $78.64M | $46.79M | $52.64M | $104.32M | $108.87M | |
| $26.43M | $29.86M | $25.64M | $27.53M | $32.61M | $28.11M | $24.78M | $101.77M | |
| — | $30.01M | $25.83M | $28.23M | $33.4M | $29.08M | $26.43M | $102.95M | |
| $1.2M | $2.89M | $720K | $5.48M | $0 | $1.09M | $17.81M | $3.89M | |
| $128.93M | $140.25M | $149.44M | $395.61M | $116.83M | $101.59M | $188.43M | $423.93M | |
| -$26.77M | -$21.54M | -$24.48M | -$243.54M | $39.41M | $9.42M | -$82.16M | -$194.43M | |
| — | -18.14% | -19.59% | -160.15% | 25.22% | 8.49% | -77.3% | -84.72% | |
| — | $8.47M | $1.35M | -$215.31M | $72.8M | $38.5M | -$55.72M | -$91.48M | |
| $3.09M | $3.08M | $3.04M | — | $7.96M | $10.22M | $15.93M | $58.39M | |
| $2.41M | $2.67M | $3.22M | $2.4M | — | — | — | — | |
| -$8.68M | -$8.4M | $2.95M | -$10.52M | -$8.24M | -$9.98M | $36.64M | -$28.06M | |
| -$35.46M | -$29.94M | -$21.53M | -$254.05M | $31.17M | -$553K | -$45.51M | -$222.48M | |
| $235K | $435K | $52K | $77.89M | -$78.46M | $728K | -$17.37M | -$5.28M | |
| -$35.69M | -$30.38M | -$21.58M | -$331.94M | $109.63M | -$1.28M | -$28.14M | -$217.2M | |
| — | -25.59% | -17.27% | -218.28% | 70.17% | -1.15% | -26.48% | -94.64% | |
| -$332.97M | — | — | -$331.94M | $109.63M | -$1.28M | -$28.14M | -$217.2M | |
| USD/shares | — | -$4.74 | -$3.40 | -$70.05 | $34.95 | -$0.45 | -$16.05 | -$184.20 |
| USD/shares | — | -$4.74 | -$3.40 | -$70.05 | $30.45 | -$0.45 | -$16.05 | -$184.20 |
| shares | — | 6.4M | 6.35M | 4.74M | 3.13M | 2.88M | 1.75M | 1.18M |
| shares | — | 6.4M | 6.35M | 4.74M | 3.64M | 2.88M | 1.75M | 1.18M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.17×
EV/EBIT
—
Peer median 36.36×
P/E (TTM)
—
Peer median 16.50×
Peer medians compare against the 51 similar-size Drug Manufacturers - Specialty & Generic companies (of 91 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Product | $117,100,000 | $120,849,000 | $149,451,000 | $155,121,000 | $109,420,000 | $92,090,000 | $108,806,000 |
| ROLVEDON | $68,225,000 | $60,090,000 | $18,175,000 | $0 | — | — | — |
| INDOCIN Products | $18,905,000 | $26,761,000 | $87,217,000 | $100,338,000 | $60,557,000 | $31,684,000 | $0 |
| Sympazan | $11,349,000 | $10,457,000 | $9,938,000 | $1,768,000 | — | — | — |
| Product Other | $10,669,000 | $15,917,000 | $4,875,000 | $4,673,000 | $5,030,000 | $7,693,000 | — |
| SPRIX Nasal Spray | $7,952,000 | $7,624,000 | $9,150,000 | $9,110,000 | $8,676,000 | $11,077,000 | $0 |
| Royalty | $1,613,000 | $2,012,000 | — | — | — | — | — |
| Product And Service Other | $0 | $2,100,000 | $185,000 | -$1,290,000 | -$985,000 | $1,408,000 | $63,855,000 |
| CAMBIA | — | $5,556,000 | $8,070,000 | $24,720,000 | $24,972,000 | $28,350,000 | $32,453,000 |
| Commercialization Agreement | — | — | — | — | $0 | $11,258,000 | $118,614,000 |
| Gralise | — | — | — | — | — | $300,000 | $63,100,000 |
| Other Revenue | — | — | — | -$1,290,000 | -$985,000 | $1,408,000 | — |
| Otrexup | — | $8,842,000 | $12,026,000 | $11,148,000 | $0 | — | — |
| Royalties and Milestones | — | $2,012,000 | $2,433,000 | $2,403,000 | $2,579,000 | $1,519,000 | $2,084,000 |
| Sympazam | — | — | — | $1,768,000 | $0 | — | — |
| Zipsor | — | — | $3,460,000 | $3,364,000 | $10,185,000 | $13,286,000 | $12,498,000 |